Literature DB >> 2428241

Prostanoid inhibition of canine parietal cells.

A H Soll, M C Chen, D A Amirian, M Toomey, R Alvarez.   

Abstract

Cellular mechanisms underlying the anti-secretory actions of the prostaglandin E2 analogue enprostil were studied using enzyme-dispersed, elutriator-enriched canine parietal cells and the accumulation of the weak base 14C-labeled aminopyrine as a functional index. Enprostil inhibited the accumulation of aminopyrine stimulated by histamine and the phosphodiesterase inhibitor isobutylmethyl, but not by carbachol, gastrin, or dibutyryl cyclic adenosine monophosphate. Inhibition by enprostil was dose-dependent (0.1 nM to 1 microM), with maximal inhibition ranging from 65 to 95 percent. Over the same concentration range, enprostil inhibited the histamine-stimulated generation of cyclic adenosine monophosphate. This selective inhibition of histamine activation of parietal cell function was comparable to that found for prostaglandin E2. Forskolin, a diterpene that directly activates the catalytic subunit of adenylate cyclase, was also markedly inhibited by nanomolar concentrations of prostaglandin E2 and enprostil. We conclude that at least a component of the secretory inhibition by enprostil reflects direct interference with histamine stimulation of parietal cell adenylate cyclase.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2428241     DOI: 10.1016/s0002-9343(86)80003-1

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  8 in total

1.  Inhibition of gastric acid secretion by epidermal growth factor. Effects on cyclic AMP and on prostaglandin production in rat isolated parietal cells.

Authors:  J F Hatt; P J Hanson
Journal:  Biochem J       Date:  1988-11-01       Impact factor: 3.857

2.  Effects of enprostil[(+/-)-11 alpha, 15 alpha-dihydroxy-9-keto-16-phenoxy-17,18,19,20-tetra-norprosta-4, 5,13-( +)- trienoic acid, methyl ester; EN] on 14C-aminopyrine (AP) accumulation in isolated canine parietal cells.

Authors:  E Saito; H Natomi; K Sugano; A Seki; F Takaku; R Yasumura; Y Matsuo
Journal:  Gastroenterol Jpn       Date:  1989-04

3.  Human jejunal secretion induced by prostaglandin E1: a dose-response study.

Authors:  I Sobhani; N Vidon; B Huchet; J C Rambaud
Journal:  Br J Clin Pharmacol       Date:  1991-04       Impact factor: 4.335

4.  Effect of two-week treatment with enprostil (35 micrograms twice a day) on 24-hour serum gastrin levels.

Authors:  C Florent; C Cogoni; M Joubert; B Desaint
Journal:  Dig Dis Sci       Date:  1990-11       Impact factor: 3.199

5.  Characterization of the prostanoid receptor profile of enprostil and isomers in smooth muscle and platelets in vitro.

Authors:  R M Eglen; R L Whiting
Journal:  Br J Pharmacol       Date:  1989-12       Impact factor: 8.739

6.  Effects of PGE2, misoprostol, and enprostil on guinea pig enterocyte adenylate cyclase. Clinical implications.

Authors:  J M Pawlotsky; P Ruszniewski; F Reyl-Desmars; M Bourgeois; M J Lewin
Journal:  Dig Dis Sci       Date:  1993-02       Impact factor: 3.199

7.  Effect of synthetic prostaglandin E2 analog enprostil on omeprazole-induced hypergastrinemia and hyperpepsinogenemia.

Authors:  J L Meijer; L F Crobach; J B Jansen; C B Lamers
Journal:  Dig Dis Sci       Date:  1994-03       Impact factor: 3.199

Review 8.  Enprostil. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of peptic ulcer disease.

Authors:  K L Goa; J P Monk
Journal:  Drugs       Date:  1987-11       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.